Navigation Links
New tool aims to improve measurement of primary care depression outcomes
Date:5/25/2011

ANN ARBOR, Mich. Primary care doctors have long been on the front lines of depression treatment. Depression is listed as a diagnosis for 1 in 10 office visits and primary care doctors prescribe more than half of all antidepressants.

Now doctors at the University of Michigan Health System have developed a new tool that may help family physicians better evaluate the extent to which a patient's depression has improved.

The issue, the researchers explain, is that the official definition of when a patient's symptoms are in remission doesn't always match up with what doctors see in a real-world practice, especially for patients with mild to moderate symptoms. The study will be published in the upcoming issue of General Hospital Psychiatry.

"Rather than simply going down a list and checking off a patient's lack of individual symptoms, we believe there are also positive signs that are important a patient's feeling that they are returning to 'normal,' their sense of well-being, their satisfaction with life and their ability to cope with life's ups and downs," says lead author Donald E. Nease Jr., M.D., who was an associate professor of family medicine at the U-M Medical School and member of the U-M Depression Center at the time of the research.

Nease and his colleagues developed a series of five questions such as, "Over the last two weeks, did you feel in control of your emotions?" that they hope will help doctors better understand a patient's inner landscape.

The remission criteria spelled out in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) doesn't necessarily correspond to a patient's own sense of recovery, Nease explains.

For example, a patient could meet all the criteria for full remission, but still not feel that he had recovered. The U-M questionnaire, which is called Remission Evaluation and Mood Inventory Tool, or REMIT, is intended to add the patient's subjective sense of recovery into the equation.

Rather than a replacement for current tools and measurements, REMIT is intended to compliment them, say Nease, who is currently an adjunct professor at U-M.

The researchers used the REMIT tool alongside the current "gold standard" for monitoring people with depression, the Patient Health Questionnaire (PHQ), Nease explains.

The data showed that by adding in the REMIT questions, about one-third of patients with mild depression were not in remission, as their PHQ score would indicate. Additionally, about one-third of moderately depressed patients were doing better than their PHQ scores alone would denote.

"Using just the PHQ score across our study population, we saw about 60 percent accuracy in reflecting a patient's remission compared to the patient's sense of his or her own recovery," Nease says. "If you add in the REMIT questions, we get above 70 percent. This can give doctors new insights when making treatment choices, such as changing a patient's medication or dosage."

The current research looked at a single snapshot in time for nearly 1,000 patients. The next step will be to track patients' scores over time.

Unlike other tools that require a company's permission to use, the REMIT tool is available to any doctor who wants to use it, Nease says.


'/>"/>

Contact: Ian Demsky
idemsky@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Brisk walking could improve prostate cancer outcomes
2. New study aims to improve long-term treatment for patients with bipolar disorder
3. Medicare improved Canadian doctors salaries: Queens University study
4. Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients
5. Tort reform reduces lawsuit risk; establishes framework for quality improvements
6. Telemonitoring can improve overall survival of HF patients
7. New tool to measure outcomes could help improve arm surgery for devastating nerve injury
8. Strobe eyewear training may improve visual abilities
9. Curcumin compound improves effectiveness of head and neck cancer treatment, U-M study finds
10. Study Finds Ovarian Screening Tests Dont Improve Survival
11. Experts explore digital technologies potential to improve health care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 ... bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for people ... such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in ...
(Date:8/18/2017)... ... August 18, 2017 , ... 800response, the ... monitoring solutions, announced today the launch of a redesigned corporate website, 800response.com ... aesthetic, fully responsive design, and an enhanced search directory for businesses and advertising ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... “Beyond Our ... fulfilled life. “Beyond Our Imaginations: The Infinite God” is the creation of published author, ... across the country. , Lawrence shares, “The problem with becoming a greater man of ...
(Date:8/18/2017)... ... 18, 2017 , ... “Prompted By Love”: a love story thrown into doubt ... Nettles. Author Mary P. Nettles has devoted her life to ministry since the ... lifelong desire to write was, however, not fulfilled until 2014 when "The Color of ...
(Date:8/17/2017)... ... August 17, 2017 , ... Shared leadership between physicians ... effective, very effective, or effective by 85% of respondents, according to the recent ... Reports are based on surveys of the NEJM Catalyst Insights Council, a qualified ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., a ... , today announced that the company has provided an ... of North Carolina at Chapel Hill and to Qura ... to characterize and quantify HIV reservoir and viral expression ... intervention. The HIV Cure Center is a joint initiative ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
Breaking Medicine Technology: